Synvista Therapeutics, Inc.
SYNI
$0.00
$0.000.00%
| 09/30/2008 | 06/30/2008 | 03/31/2008 | 12/31/2007 | 09/30/2007 | |
|---|---|---|---|---|---|
| Revenue | -27.27% | 3.40% | -- | -17.71% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -27.27% | 3.40% | -- | -17.71% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -27.27% | 3.40% | -- | -17.71% | -- |
| SG&A Expenses | 35.39% | 59.56% | -27.21% | -40.70% | 16.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.28% | 18.31% | 54.14% | 25.24% | 110.08% |
| Operating Income | 7.27% | -18.63% | -54.00% | -26.48% | -110.01% |
| Income Before Tax | 34.20% | 44.54% | 32.37% | -173.01% | 68.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.20% | 44.54% | 32.37% | -173.01% | 68.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.20% | 44.54% | 32.37% | -173.01% | 68.99% |
| EBIT | 7.27% | -18.63% | -54.00% | -26.48% | -110.01% |
| EBITDA | 7.28% | -18.59% | -81.73% | -27.01% | -111.45% |
| EPS Basic | 15.22% | 4.48% | -27.71% | -412.52% | 64.34% |
| Normalized Basic EPS | 34.20% | 51.81% | 32.36% | -18.52% | -154.83% |
| EPS Diluted | 15.22% | 4.48% | -27.71% | -412.52% | 64.34% |
| Normalized Diluted EPS | 34.20% | 51.81% | 32.36% | -18.52% | -154.83% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | -0.32% | 16.88% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | -0.32% | 16.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
